Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Feb 04, 2025
Episode
259
Soundcloud
Share
This episode of Lung Cancer Considered covers the recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC, based on the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Host Dr. Narjust Florez goes in depth with podcast guest Dr. Pamela Samson about the LAURA Trial and its implications for patients and clinicians.
Guest
Pamela Samson
MD
Assistant Professor in the Department of Radiation Oncology
Washington University, St. Louis
